|1.||Seri, S: 2 articles (10/2005 - 10/2005)|
|2.||Nakatani, Akira: 2 articles (10/2005 - 11/2004)|
|3.||Hashiguchi, Yuji: 2 articles (10/2005 - 11/2004)|
|4.||Ogino, Hiroyuki: 1 article (06/2006)|
|5.||Shiraki, Norio: 1 article (06/2006)|
|6.||Kasai, Harumasa: 1 article (06/2006)|
|7.||Miyati, Tosiaki: 1 article (06/2006)|
|8.||Ito, Masato: 1 article (06/2006)|
|9.||Mase, Mitsuhito: 1 article (06/2006)|
|10.||Oshima, Hidekazu: 1 article (06/2006)|
06/01/2006 - "Contrast enhancement by NMS60 was excellent at both concentrations, and when tumor detectability was assessed with a five-point scale, the diagnostic usefulness was 4 or higher in all cases. "
11/01/1999 - "NMS60 showed significantly greater peak enhancement in muscle, tumor rim, and core compared to DTPA in both T1-weighted and SPGR images. "
11/01/1999 - "The intermediate weight contrast agent NMS60 offers greater tumor enhancement than Gd-DTPA and may offer improved regional differentiation on the basis of vascular permeability in tumors."
11/01/1999 - "NMS60 also showed delayed peak enhancement in the dynamic scans (compared to Gd-DTPA) and significantly reduced leakage rate constant into the extravascular space for tumor rim (K21 = 5.1 min(-1) vs. 11.5 min(-1) based on a 2 compartment kinetic model). "
11/01/1999 - "Dynamic contrast-enhanced MRI of Implanted VX2 tumors in rabbit muscle: comparison of Gd-DTPA and NMS60."
|2.||Pathologic Constriction (Stenosis)
11/01/2004 - "An MRA study of vascular stenosis in a pig model using CH3-DTPA-Gd (NMS60) and Gd-DTPA."
11/01/2004 - "This study used an experimental arterial stenosis model in pigs to evaluate the utility of a new medium-weight MRI contrast agent, NMS60 (a synthetic oligomeric Gd complex containing three Gd(3+) atoms, molecular weight of 2158 Da) compared to Gd-DTPA for contrast-enhanced MRA. "
|3.||Brain Neoplasms (Brain Tumor)
06/01/2006 - "We report on our early phase II study on NMS60 in brain tumor patients together with supplementary investigations. "
06/01/2006 - "Evaluation of CH3-DTPA-Gd (NMS60) as a new MR contrast agent: early phase II study in brain tumors and dual dynamic contrast-enhanced imaging."
06/01/2006 - "An NMS60 dose of 0.1 or 0.2 mmol (Gd)/kg was randomly assigned and administered to 10 patients (five women, five men; mean age: 49 years) with brain tumors. "
|5.||Myocardial Ischemia (Ischemic Heart Diseases)
10/01/2005 - "A comparison of CH3-DTPA-GD (NMS60) and GD-DTPA for evaluation of acute myocardial ischemia."
10/01/2005 - "Our objective was to evaluate the use of a new medium weight MRI contrast agent, NMS60 (a synthetic oligomeric Gd-complex containing three Gd(3+) atoms, molecular weight 2158 Da) compared to gadolinium-diethylene triamine pentaacetic acid (Gd-DTPA) in a pig myocardial ischemia model. "
|1.||Gadolinium DTPA (Magnevist)
|2.||Pentetic Acid (DTPA)
|3.||GD3 ganglioside (GD(3))